2.13. Analysis.
Comparison 2 Leukotriene Receptor Antagonists (LTRA) + ICS vs. DOUBLE dose of ICS in SYMPTOMATIC PATIENTS, Outcome 13 Change from baseline mean daily use of B2‐agonists at HIGHER THAN LICENSED DOSES at 12 +/‐ 4 weeks.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.